Antibody - Articles - Page 25

Endocrine/Metabolic

Scholar Rock to advance myostatin inhibitor toward IND submission for obesity

Oct. 13, 2023

Scholar Rock Inc. has announced plans to advance SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity, toward an IND submission in 2025.

Newco news

Rezolute preps for phase III with rare, pediatric disorder drug

Oct. 6, 2023

By Caroline Richards

In the ultra-rare disease congenital hyperinsulinism, an overproduction of insulin leads to persistent hypoglycemia and can cause neurological complications due to high glucose needs of the brain. About half of children go on to develop seizures or intellectual problems, but current therapeutic options are limited and there are no approved drugs specifically for the condition.

Drug Design, Drug Delivery & Technologies

NIH funding supports Integral Molecular’s discovery of antibodies

Oct. 6, 2023

Integral Molecular Inc. has been awarded funding totaling $896,000 from the National Institutes of Health (NIH), which will support its discovery of antibodies against difficult and conserved protein targets.

Drug Design, Drug Delivery & Technologies

Twist Bioscience and Bayer sign antibody discovery, option and license agreement

Oct. 6, 2023

Twist Bioscience Corp. has entered into an antibody discovery, option and license agreement with Bayer AG.

Illustration of pancreas, close up of islet

Endocrine/Metabolic

Sab Biotherapeutics raises funds to advance treatment for type 1 diabetes

Oct. 3, 2023

Sab Biotherapeutics Inc. has announced a private placement of up to $130 to fund the company’s lead research program, SAB-142, a potential disease-modifying treatment for type 1 diabetes. SAB-142 is expected to advance into clinical trials in the fourth quarter of this year.

Infection

New therapeutic strategy based on cow antibodies demonstrates antiviral efficacy

Oct. 3, 2023

Complementarity-determining regions (CDRs) are relatively short peptide loops in antibodies where they bind to their specific antigens. Bovines, unlike humans and other vertebrates, rely on ultralong CDR H3 antibody knob regions to neutralize cryptic viral epitopes.

Inflammatory

Twist Bioscience and Imidomics enter antibody discovery collaboration for immune-mediated inflammatory diseases

Sep. 28, 2023

Twist Bioscience Corp. and Imidomics Inc. have established a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by Imidomics.

AI generated illustration of a brain on fire

Neurology/Psychiatric

Newco news: Arialys has autoimmune solution to psychosis problem

Sep. 27, 2023

By Anette Breindl

Arialys Therapeutics Inc. launched this month with $58 million in seed funding, an experimental compound it is developing for autoimmune encephalitis and autoimmune psychosis, and high aspirations for its field. “Yes, I want to treat these patients, I want these patients to have a better life. But I also want drug discovery and development folks to think differently about discovering new drugs for the CNS,” Jay Lichter told BioWorld.

Immuno-oncology

Glycotope and Max Delbrück Center collaborate to explore combined use of Glycotargets and CAR technology

Sep. 26, 2023

Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (Glycotargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

Inflammatory

New Celexor Bio to focus on cell depletion of pathologic cells in autoimmune and inflammatory disorders

Sep. 22, 2023

Inmagene Biopharmaceuticals Technology (Shanghai) Co. Ltd. and biotech investment firm Aditum Bio Management Company LLC have announced the formation of Celexor Bio, a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders. Celexor has been formed based on Inmagene’s IMG-018, a plasmacytoid dendritic cell (pDC)-depleting antibody targeting immunoglobulin-like transcript 7 (ILT7).

Antibody
RSS

Scholar Rock to advance myostatin inhibitor toward IND submission for obesity

Rezolute preps for phase III with rare, pediatric disorder drug

NIH funding supports Integral Molecular’s discovery of antibodies

Twist Bioscience and Bayer sign antibody discovery, option and license agreement

Sab Biotherapeutics raises funds to advance treatment for type 1 diabetes

New therapeutic strategy based on cow antibodies demonstrates antiviral efficacy

Twist Bioscience and Imidomics enter antibody discovery collaboration for immune-mediated inflammatory diseases

Newco news: Arialys has autoimmune solution to psychosis problem

Glycotope and Max Delbrück Center collaborate to explore combined use of Glycotargets and CAR technology

New Celexor Bio to focus on cell depletion of pathologic cells in autoimmune and inflammatory disorders

Today's news in brief

Today's news in brief

Circode applies circRNA to heart disease drug R&D, in vivo CAR T

BD’s biosciences & diagnostics unit in $17.5B merger with Waters

News in brief

Antibody RSS

Antibody
RSS